Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biomarker Levels Prognostic for Septic Patients

By LabMedica International staff writers
Posted on 17 Sep 2012
An elevation in soluble urokinase-type plasminogen activator receptor (suPAR) levels may predict case fatality and is associated with severe sepsis. More...


The suPAR protein levels in the blood and other biomarkers, such as procalcitonin, have been evaluated as early prognostic markers of sepsis in patients with suspected infection

At the Satakunta Central Hospital (Pori, Finland) scientists conducted a prospective cohort study on 539 patients in the emergency department with suspected infection. The patients were divided into the following groups: in group1 comprised of 59 patients without systemic inflammatory response syndrome (SIRS) and without bacterial infection; group 2 were 68 patients with bacterial infection and without SIRS; group 3 were 54 patients with SIRS and without bacterial infection; group 4 were 309 patients with sepsis (SIRS and bacterial infection) and without organ failure and Group 5 were 49 patients with severe sepsis (SIRS, bacterial infection and organ failure.

Plasma suPAR levels were determined using a commercial double monoclonal antibody sandwich enzyme immunoassay (suPARnostic Standard Kit, ViroGates; Birkerød, Denmark). Procalcitonin (PCT) and interleukin-6 (IL-6) in plasma were measured with immunochemiluminometric assays in a Modular E170 automatic analyzer (Roche Diagnostics GmbH, Mannheim, Germany). C-reactive protein (CRP) in plasma was measured with an immunoturbidimetric assay using a Roche Diagnostics Modular P800 automatic analyzer.

The median suPAR concentrations were 4.7, 5.0, 4.4, 4.8, and 7.9 ng/mL in groups 1 through 5, respectively and levels were found to be significantly higher at 8.3 ng/mL in nonsurvivors compared with in survivors at 4.9 ng/mL. The suPAR level was found to have 76% sensitivity and 69% specificity for fatal disease, using a cut-off level of 6.4 ng/mL and 67% and 72% sensitivity and specificity, respectively, for severe sepsis at a cut-off level of 6.6 ng/mL. The scientists also evaluated PCT, interleukin 6, and C-reactive protein in this patient population and found that although suPAR was the best biomarker for case fatality, in further statistical analysis, PCT was a superior marker for severe sepsis.

The authors concluded, "It is tempting to think that measurement of suPAR may be used for triage to determine which patients with sepsis may require more comprehensive monitoring, as high suPAR levels in the emergency department may predict the need for more intensive therapeutic intervention." The study was published in the September 2012 issue of the Journal of Internal Medicine.

Related Links:

Satakunta Central Hospital
ViroGates
Roche Diagnostics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Urine Analyzer
respons® UDS100
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.